Loading
Life sciences · Journal article
Frontiers in Immunology · November 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
UL16-binding protein 2 (ULBP2) is a stress-inducible NKG2D ligand whose expression has been linked to both tumor recognition and poor clinical outcomes. These observations are difficult to interpret from expression measurements alone. We review evidence on ULBP2 regulation, immune function, and therapeutic targeting, distinguishing surface ligand from intracellular and soluble protein. Shedding can weaken tumor-cell recognition by removing surface ULBP2, whereas the direct suppressive effects of soluble ULBP2 vary across experimental systems. Persistent surface expression also reduced NKG2D expression and cytotoxicity in an engineered murine model. Recent tumor-type-specific perturbation studies implicate ULBP2 in MAPK-associated malignant phenotypes, TGF-β-linked fibroblast and extracellular-matrix responses, and radioresistance. These findings extend the functional landscape of ULBP2 beyond immune recognition, although direct receptor-proximal mechanisms remain unresolved. We propose the ULBP2 State Model as a working framework that considers accessible surface abundance, localization, molecular form, and exposure duration alongside the immune-stromal environment and treatment context. Therapeutic approaches include controlling ligand shedding, redirecting effector cells with ULBP2-containing immunoligands, NKG2D-based cellular therapies, and direct ULBP2-specific chimeric antigen receptor (CAR) targeting. A central implication is that ULBP2 associated with impaired endogenous immunity may still provide an antigen for engineered cellular therapies. Together, these findings support a shift from expression-based to state-resolved interpretation of ULBP2. The ULBP2 State Model links ligand biology with immune function and therapeutic vulnerability, providing a framework for understanding how the same molecule can mediate immune recognition, immune adaptation, and therapeutic targeting in different contexts.